Abstract
Beta lactams are standard empirical therapy for febrile neutropenia (FN). The aim of this study was to evaluate the efficacy and safety of cefepime monotherapy compared with cefoperazone/sulbactam plus amikacin (CS + A) for empirical treatment of high risk FN. One hundred seventy-five patients with 336 FN episodes were randomized to receive either cefepime (2 g q8h for adults and 50 mg/kg q8h for children) or CS (2 g q8h for adults and 50 mg/kg q8h for children) plus amikacin (15 mg/kg once a day). Positive response was defined as afebrile within 72 h of starting antibiotics, persistent afebrile status more than 48 h and no requirement of second-line antibiotics and antifungal agents. Three hundred thirty-six episodes were assessable for efficacy (168 cefepime, 168 CS + A). The positive response to antibiotics was identical for cefepime (53%) and CS + A (53%). Positive response was similar in MDI (microbiologically documented infection), 50 vs. 35% (p = 0.248), CDI (clinically documented infection), 50 vs. 35% (p = 0.259), combination CDI + MDI, 25 vs. 15% (p = 0.400), FUO (fever of unknown origin), 68 vs. 72% (p = 0.577) respectively in the two groups. The successful discontinuation of antibiotics at 72 h in FUO was similar in...Continue Reading
References
Nov 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W T HughesL S Young
Jul 1, 1994·Cancer·R O BashG R Buchanan
Mar 1, 1997·Medical and Pediatric Oncology·V M AquinoM M Mustafa
Nov 18, 1998·The Journal of Antimicrobial Chemotherapy·P BironJ J Grès
Oct 31, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R FeldW Ho
Jul 4, 2002·The Journal of Antimicrobial Chemotherapy·Miguel A SanzUNKNOWN Spanish PETHEMA Group
Nov 26, 2002·American Journal of Hematology·K TamuraUNKNOWN Kyushu Hematology Organization for Treatment (K-HOT) Study Group
Apr 1, 2006·Cancer·Nicole M KudererGary H Lyman
Oct 24, 2006·Bone Marrow Transplantation·E R DubberkeH J Khoury
Jan 22, 2008·Japanese Journal of Clinical Oncology·Ki Tae KwonJae-Hoon Song
May 8, 2010·Indian Journal of Cancer·K PrabhashR Kelkar
Jan 25, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alison G Freifeld Infectious Diseases Society of America
Feb 22, 2011·Medical Oncology·Indranil GhoshArti Kapil
Jun 16, 2011·Pediatric Blood & Cancer·Serap KaramanRejin Kebudi
Jan 16, 2013·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Takahiko YasudaTomoki Naoe
Dec 11, 2013·Haematologica·Diana AverbuchUNKNOWN ECIL4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN
Jan 1, 2014·International Journal of Clinical Practice·O R SipahiS Ulusoy
Dec 31, 2014·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Prakas Kumar MandalMaitreyee Bhattacharyya
Oct 1, 2014·Indian Journal of Cancer·L A JacobR S Jayashree
Sep 24, 2016·Infection & chemotherapy·Joon Hee LeeHack Ki Kim
Sep 25, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J KlasterskyUNKNOWN ESMO Guidelines Committee
Oct 1, 2016·Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology·K Govind BabuR S Jayshree
Citations
Jan 29, 2019·Expert Review of Anti-infective Therapy·Martin Schmidt-HieberEnrico Schalk
Feb 23, 2020·Medicine·Shao-Huan LanHung-Jen Tang
May 24, 2020·Medicine·Katerina ToriEleftherios Mylonakis
May 27, 2020·The Pediatric Infectious Disease Journal·Na Hee LeeYae-Jean Kim
Jun 3, 2020·Medicine·Katerina ToriEleftherios Mylonakis
Dec 1, 2020·Deutsche medizinische Wochenschrift·Winfried V KernGeertje Fink